Subscribe to 

CURE magazine!


CURExtra ASCO 2013
ASCO 2013

Photo Courtesy of ASCO/Scott Morgan 2013

Top Research News Announced in Several Cancers

The American Society of Clinical Oncology (ASCO) hosted its annual meeting in Chicago from May 31 to June 4, attracting more than 32,000 cancer researchers, physicians, industry professionals, advocates and survivors to report on advances in cancer care, screening, treatment and prevention.

CURE has compiled the top stories from ASCO that will impact patients, survivors and caregivers immediately and in the near future. Here's a preview of coverage from the Summer issue.

Additional coverage and insight from ASCO are included below:

Suzanne Lindley
ASCO: Big Meeting for Cancer Patients
Kathy LaTour, CURE's editor-at-large, says she's growing impatient for a huge breakthrough in cancer: "I know that we really are on the cusp of personalized cancer treatment for each person, but maybe it's just not happening fast enough. Every time I have a friend diagnosed, I am reminded that it's not happening fast enough." READ BLOG >

Michael Wong, MD
PD-1 Inhibitors Are a Game Changer
Michael Wong, melanoma oncologist and CURE advisory board member, explains how recent studies are targeting the PD-1 pathway and describes why there is so much excitement surrounding this new class of immunotherapy. VIEW VIDEO >

Debu Tripathy, MD
Updates in HER2-Positive Breast Cancer
Debu Tripathy, breast oncologist and CURE's editor-in-chief, describes the results of HER2-positive breast cancer studies presented at this year's meeting. VIEW VIDEO >

New Class of Therapies Could Benefit Melanoma, Other Cancers
The promise of training the body to recognize and kill cancer cells—without the damaging side effects of traditional cancer therapy—has intrigued us for years. But we now have a handful of immunotherapy drugs approved for cancer treatment, and many more on the horizon, it seems, from the studies released at the ASCO's annual meeting. READ BLOG >

Let's Talk About Sex
Sex is one topic that always seems to generate interest, even at a cancer research conference. Among the many studies presented at this year's annual meeting: a first-of-its-kind examination of spouses or long-term partners of patients with HPV-positive oropharyngeal cancers, which are located at the tongue, tonsils, pharynx and soft palate. READ BLOG >

Nexavar Halts Thyroid Cancer Progression for Five Months
The kinase inhibitor Nexavar (sorafenib), already approved for kidney and liver cancers, has been shown to keep thyroid cancer from progressing for five months, according to results of a phase 3 study. READ BLOG >

Small Gain in Ocular Melanoma Equals Big News
In a cancer that doesn't have many treatment options, any gains are considered a success. Uveal melanoma, although rare, is the most common eye cancer in adults, affecting nearly 2,500 individuals a year. READ BLOG >

Erbitux Edges Ahead of Avastin for Newly Diagnosed Metastatic Colorectal Cancer
In the FIRE-3 study, Erbitux (cetuximab) came out ahead in overall survival compared with Avastin (bevacizumab) for treating patients with newly diagnosed metastatic colorectal cancer.

Avastin Fails to Provide Benefit for Patients with Newly Diagnosed Glioblastoma
A disappointing showing of a phase 3 study found that Avastin (bevacizumab) did not prolong survival in newly diagnosed glioblastoma. READ BLOG >




Combining science with humanity, CURE makes cancer understandable.

Send feedback to

This email was sent to you because you have provided your email address to CURE. CURE is committed to protecting your privacy, and no information about our subscribers is sold to any outside party.

© 2013 CURE Media Group.
3102 Oak Lawn Ave, Ste. 610, Dallas, TX 75219
All rights reserved.

Disclaimer: CURE does not provide medical, diagnostic or treatment advice. Terms of Use